The number of targeted drugs used for cancer treatment is steadily increasing. In contrast to conventional chemotherapy, these drugs do not act as undirected cell toxins, but rather inhibit certain processes in cell metabolism. Although we are aware of the molecules that these drugs target, the reasons for whether treatment is effective or not in individual patients very often remain obscure.
Pazopanib (brand name: Votrient) has been used for several years to treat patients with soft tissue sarcomas and is currently the only targeted therapy in this disease group. On average, pazopanib treatment leads to a stabilization of the sarcoma disease over a period of 4-5 months. However, there are also patients for whom in exceptional cases pazopanib works well and over the longer term. The reasons for this are still unknown.